Oncology News Central

?? Founded in 2023, Common Sense Oncology is on a mission to reform how cancer drugs are developed and approved, focusing on outcomes that truly matter to patients. With input from clinicians, policy makers, and patient advocates globally, this initiative led by Dr. Bishal Gyawali recently published FAQs on the pitfalls of surrogate endpoints in oncology. Their sessions at ASCO and ESMO have drawn significant attention, and their growing membership is a testament to their impact. Learn how this movement is reshaping oncology care and trial design. https://bit.ly/3YoMCtP Common Sense Oncology Bishal Gyawali

More than 25% of patients used drugs later withdrawn after failed trials under the FDA’s Accelerated Approval Program. Clinicians must share this info for informed decisions, says Reshma Ramachandran, MD. bit.ly/3Z8mzpM

What Matters Most to Cancer Patients: Certainty vs. Speed? A new study published in Lancet Oncology challenges assumptions about patient priorities under the FDA's Accelerated Approval Program. The study found that older adults with experience in cancer care value certainty of survival benefit more than faster access to new drugs based on surrogate endpoints. Key Findings: ?? Patients were willing to wait 21+ months for drugs with a high certainty of benefit. ?? Surrogate endpoints had no significant influence on their decisions. Tap for more on the research. Robin Forrest, MSc and Aaron Mitchell, MD break down the data. https://bit.ly/3Z4WpUR Robin Forrest Aaron Mitchell The Lancet

Who’s leading in pediatric cancer care? Cincinnati Children’s & Dana-Farber/Boston Children’s top the 2024–25 @usnews rankings, with CHOP making a big leap to 3rd place. See the full list: bit.ly/3YT1GPq Cincinnati Children's Dana-Farber Cancer Institute Children's Hospital of Philadelphia U.S. News & World Report Steve Davis, MD MMM MS Ben Harder

Join us at #ASH24 for a Onc Brothers live event, "Advancements in Oncology: Today’s Data for Tomorrow’s Practice," hosted in person by Drs Rahul & Rohit Gosain. 12/8/24 - 6:30-8:30 PM PST. Register here: bit.ly/3AHFb88 Rohit Gosain, MD Rahul Gosain, MD, MBA Ann LaCasce Hetty Carraway Amer Zeidan Vincent Rajkumar Andrew M. Evens, DO, MBA, MSc Caitlin Costello SignifyMD ? ?

‘It’s really powerful. Both of those communities are really tight-knit, and it’s really cool to come into that community and feel like you’re a part of it.’ – Dr. Kate Baker on providing cancer care in rural TN. https://bit.ly/3CAk9sl Kate Baker Community Oncology Alliance Tennessee Oncology Shiela Plasencia Stephen Schleicher

Achieving a good, peaceful death' remains elusive for many cancer patients. Dr. Sunita Puri and Dr. Robert Figlin call for a national conversation on this vital issue. https://bit.ly/3ymPXze

"Community oncologists are already adept at balancing the complexity of diverse cancer types & patient needs while navigating emerging treatment innovations," says Ramy Sedhom, MD. The future of cancer care is collaboration & community oncology. https://bit.ly/3Zfvl6H Ramy Sedhom Penn Medicine, University of Pennsylvania Health System

Small cell lung cancer (#SCLC) treatment has reached new heights in 2024 with practice-changing developments: ?? The first-ever FDA approval of a bispecific antibody in SCLC. ?? Promising Phase 3 data renewing confidence in lurbinectedin (Zepzelca). ?? Game-changing survival outcomes with durvalumab (Imfinzi), establishing a new standard of care. These lung cancer breakthroughs signal hope for patients and a shift in clinical practice. How are you incorporating these advances into your SCLC treatment strategies? https://bit.ly/491AcMe Joshua Sabari Vivek Subbiah, MD Roy Herbst David R. Spigel, MD Stephen Liu American Society of Clinical Oncology (ASCO)

?? Surrogate endpoints under scrutiny in oncology. Common Sense Oncology challenges the use of endpoints like PFS in drug approvals, calling for better patient-centered measures. Dr. Bishal Gyawali breaks it down. https://bit.ly/3BO8Lc7 Bishal Gyawali